Healthcare entity
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Drug Enforcement Administration (DEA), the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline.
Last mentioned: Jul 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Drug Enforcement Administration (DEA), the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 1 Healthcare story that mention MMJ BioPharma Labs, Inc., all published on July 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MMJ BioPharma Labs, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Scheduled DEA hearing on rescheduling
A DEA administrative hearing is set to take place, which CEO Duane Boise calls less significant than the appellate court action.
MMJ announces advancement of legal challenge
Company issues press release declaring that the D.C. Circuit challenge has advanced and that the operative legal event is the court review, not the upcoming DEA hearing.
Statement of Issues filed
MMJIH files a Statement of Issues in the D.C. Circuit Court of Appeals seeking vacatur of the Final Order.
Acting Attorney General issues Final Order
Todd Blanche places marijuana into Schedule III of the Controlled Substances Act via a Final Order.
Initial DEA hearing process begins
A hearing process on marijuana rescheduling begins under the Controlled Substances Act, later terminated by the government according to petitioners.
MMJ International Holdings' appeal to the D.C. Circuit exposes a procedural flaw in the DEA's marijuana rescheduling that could delay patient access to new cannabinoid medicines and create confusion for healthcare providers trying to navigate the shifting regulatory landscape.
Source: tennesseedaily.com · pr-inside.com
MMJ BioPharma Labs, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
